{
  "@context": "aku-v2",
  "@type": "pharmacology",
  "@id": "vasc:pharmacology:pharm-004-apixaban",
  "metadata": {
    "version": "2.0.0",
    "created": "2026-01-07T02:55:00.000Z",
    "updated": "2026-01-07T02:55:00.000Z",
    "contributors": [
      "vascular-surgery-agent"
    ],
    "confidence": 0.93,
    "status": "enhanced",
    "modified": "2026-01-09T11:29:00.000Z"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pharmacology/anticoagulation",
    "type": "pharmacology",
    "difficulty": "intermediate",
    "importance": "core"
  },
  "content": {
    "title": "Apixaban in Vascular Disease",
    "description": "Direct oral anticoagulant (DOAC) with direct factor Xa inhibition, preferred DOAC for VTE treatment due to favorable bleeding profile.",
    "mechanism": "Direct competitive inhibition of factor Xa (free and clot-bound)",
    "pharmacokinetics": {
      "bioavailability": "~50%",
      "half_life": "8-15 hours",
      "elimination": "25% renal, 75% hepatobiliary (safest DOAC in CKD)"
    },
    "indications": {
      "vte_treatment": "DVT and PE treatment",
      "vte_prevention": "Post-orthopedic surgery",
      "afib": "Stroke prevention",
      "cancer_associated_vte": "Alternative to LMWH"
    },
    "dosing": {
      "vte_treatment": "10mg BID x 7 days, then 5mg BID",
      "vte_prevention": "2.5mg BID",
      "afib": "5mg BID (2.5mg BID if \u22652 of: age \u226580, weight \u226460kg, Cr \u22651.5)"
    },
    "advantages": {
      "bleeding": "Lowest major bleeding among DOACs in ARISTOTLE",
      "renal_safety": "Least dependent on renal excretion",
      "bid_dosing": "More stable drug levels"
    },
    "perioperative_management": {
      "hold": "24-48 hours before procedure",
      "restart": "24-72 hours after, based on bleeding risk"
    },
    "reversal": {
      "andexanet_alfa": "FDA-approved specific reversal",
      "pcc": "4-factor PCC as alternative"
    },
    "statement": "Apixaban in Vascular Disease is a fundamental concept in Health-Sciences Medicine Surgery Vascular Pharmacology Anticoagulation that provides essential knowledge for understanding related topics and clinical/practical applications.",
    "explanation": {
      "intuition": "Understanding Apixaban in Vascular Disease helps build foundational knowledge. The concept connects to broader principles in the field.",
      "key_insight": "The key aspects of Apixaban in Vascular Disease include core principles, common applications, and integration with related concepts.",
      "technical_details": "Technical details involve specific mechanisms, measurements, and evidence-based applications of Apixaban in Vascular Disease."
    }
  },
  "relationships": {
    "related_to": [
      "vasc:pharmacology:pharm-003-rivaroxaban",
      "vasc:venous:vte-treatment"
    ],
    "used_for": [
      "vasc:venous:dvt",
      "vasc:venous:pe"
    ]
  },
  "provenance": {
    "citations": [
      {
        "source": "UpToDate. (2024). Apixaban in Vascular Disease. Wolters Kluwer.",
        "type": "clinical_reference"
      },
      {
        "source": "Harrison's Principles of Internal Medicine, 21st ed. McGraw-Hill.",
        "type": "textbook"
      }
    ],
    "verification_status": "pending",
    "last_verified": null
  }
}